
The Lenskart IPO enters its second day of subscription today, 3 November 2025. Till the end of day 1, the IPO received a total subscription of 1.13 times, with the highest interest from Qualified Institutional Buyers (QIBs) at 1.42 times. The bidding window is scheduled to close on November 4, 2025.
The Lenskart IPO is a book-building issue of ₹7,278.02 crores, comprising a fresh issue of ₹2,150.00 crores and an offer-for-sale of ₹5,128.02 crores. The price band is set between ₹382 and ₹402 per share. The basis of allotment will be finalised by November 6, 2025, and the tentative listing date on NSE and BSE is November 10, 2025.
The book-running lead managers for the IPO are Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, Avendus Capital Private Limited, Citigroup Global Markets India Private Limited, Axis Capital Limited, and Intensive Fiscal Services Private Limited, while Bigshare Services Private Limited serves as the registrar for the issue.
[3-November-2025 17:00:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
1.64 |
|
Non-Institutional Investors |
1.88 |
|
Retail Individual Investors (RIIs) |
3.33 |
|
Employees |
2.62 |
|
Total |
2.01 |
[31-October-2025 17:00:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
1.42 |
|
Non-Institutional Investors |
0.41 |
|
Retail Individual Investors (RIIs) |
1.31 |
|
Employees |
1.10 |
|
Total |
1.13 |
The company will not receive any proceeds from the OFS (offer for sale) component; instead, they will be directly allocated to the selling shareholders.
The net proceeds from the fresh issue will be distributed towards
Lenskart is a D2C (direct-to-consumer) company engaged in the business of designing, manufacturing, branding and retailing eyewear products. The company sells prescription eyeglasses, sunglasses, contact lenses and other eyewear accessories.
According to the Redseer Report, Lenskart was the largest seller of prescription eyeglasses in terms of volumes sold in India in FY 2025.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.